Shandong Wohua Pharmaceutical Co (SZSE:002107) 3-Year EBITDA Growth Rate : -30.10% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co 3-Year EBITDA Growth Rate?

Shandong Wohua Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.02.

During the past 12 months, Shandong Wohua Pharmaceutical Co's average EBITDA Per Share Growth Rate was -58.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -30.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 2.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shandong Wohua Pharmaceutical Co was 80.40% per year. The lowest was -41.10% per year. And the median was 5.90% per year.

Competitive Comparison of Shandong Wohua Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Wohua Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Wohua Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Wohua Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shandong Wohua Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Shandong Wohua Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shandong Wohua Pharmaceutical Co (SZSE:002107) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shandong Wohua Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011

Website

http://www.wohua.cn

Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines